CIK 0001501697
- Non-accelerated filer
- Smaller reporting company
X4 Pharmaceuticals, Inc
Sign in to watch- Ticker
- XFOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 273181608
- Phone
- +1 857-529-8300
- Business address
- 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
- Former names
- Arsanis, Inc.
- Open-market buys, last 90 days
- $11,884
- in 1 filing
- Open-market sales, last 90 days
- $33,658
- in 1 filing
Net −$21,775. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-20 | EMBL Technology Fund II GmbH & Co. KG 10% owner | Purchase | +20,000 | $10.00 | $200K | 370,454 |
| 2017-11-20 | EMBL Technology Fund II GmbH & Co. KG 10% owner | Conversion · Series C Convertible Preferred Stock | −207,253 | 0 | ||
| 2017-11-20 | EMBL Technology Fund II GmbH & Co. KG 10% owner | Conversion · Series D Convertible Preferred Stock | −843,613 | 0 | ||
| 2017-11-20 | NeoMed Innovation V L.P. 10% owner | Conversion | +246,682 | 246,682 | ||
| 2017-11-20 | NeoMed Innovation V L.P. 10% owner | Conversion | +41,878 | 288,560 | ||
| 2017-11-20 | NeoMed Innovation V L.P. 10% owner | Conversion | +279,079 | 567,639 | ||
| 2017-11-20 | NeoMed Innovation V L.P. 10% owner | Purchase | +300,000 | $10.00 | $3.0M | 867,639 |
| 2017-11-20 | NeoMed Innovation V L.P. 10% owner | Conversion · Series B Convertible Preferred Stock | −552,487 | 0 | ||
| 2017-11-20 | NeoMed Innovation V L.P. 10% owner | Conversion · Series C Convertible Preferred Stock | −84,040 | 0 | ||
| 2017-11-20 | NeoMed Innovation V L.P. 10% owner | Conversion · Series D Convertible Preferred Stock | −952,497 | 0 | ||
| 2017-11-20 | GV 2016 GP, L.L.C. 10% owner | Conversion | +451,362 | 451,362 | ||
| 2017-11-20 | GV 2016 GP, L.L.C. 10% owner | Conversion · Series D Convertible Preferred Stock | −1,540,499 | 0 | ||
| 2017-11-20 | Nessi Claudio Director | Conversion | +246,682 | 246,682 | ||
| 2017-11-20 | Nessi Claudio Director | Conversion | +41,878 | 288,560 | ||
| 2017-11-20 | Nessi Claudio Director | Conversion | +279,079 | 567,639 | ||
| 2017-11-20 | Nessi Claudio Director | Purchase | +300,000 | $10.00 | $3.0M | 867,639 |
| 2017-11-20 | Nessi Claudio Director | Conversion · Series B Convertible Preferred Stock | −552,487 | 0 | ||
| 2017-11-20 | Nessi Claudio Director | Conversion · Series C Convertible Preferred Stock | −84,040 | 0 | ||
| 2017-11-20 | Nessi Claudio Director | Conversion · Series D Convertible Preferred Stock | −952,497 | 0 | ||
| 2017-11-20 | Anna-Maria & Stephen Kellen Foundation, Inc. 10% owner | Conversion | +25,819 | 25,819 |
Page 15 of 25 · 490 trades